Klotho Neurosciences, Inc.
KLTO•NASDAQ•Healthcare•Biotechnology

About Klotho Neurosciences

Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer’s disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig’s disease. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOJoseph Sinkule
Founded2019
Employees3
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock

Contact Information

Websiteklothoneuro.com
Phone833 931 6330
Address
13576 Walnut Street, Suite A Omaha, Nebraska 68144 United States

Corporate Identifiers

CIK0001907223
CUSIP49876K103
ISINUS49876K1034
EIN86-2727441
SIC2836

Leadership Team & Key Executives

Dr. Joseph Sinkule Pharm.D.
Founder, Chief Executive Officer, Chairman of the Board and Secretary
Jeffrey LeBlanc
Chief Financial Officer
Dr. Shalom Z. Hirschman M.D.
Medical Advisor and Director
Peter J. Moriarty
Chief Business Officer
Dr. Miguel Chillon Rodriguez
Chief Scientific Officer and Consultant